Vonoprazan Fumarate Tak-438 Powder CAS 1260141-27-2

Product name TAK-438
CAS 1260141-27-2
Molecular Formula C21H20FN3O6S
Molecular weight 461.4634032
Apperance White powder
purity 99%

Categories:

Product Name: Vonoprazan Fumarate (Tak-438)
CAS No.: 1260141-27-2
LogP: 3.82910
Molecular Formula: C21H20FN3O6S
PSA: 147
Molecular Weight: 461.4634032
Exact Mass: 461.105682
InChIKeys: ROGSHYHKHPCCJW-WLHGVMLRSA-N
H-bond Acceptor: 9
H-bond Donor: 3
SP3: 0.10
Categories: Inhibitor Drugs

Application & Function

1. Compared with the traditional proton pump inhibitor lansoprazole, Vonoprazan works by competitively and reversibly inhibiting K+ in the proton pump. Clinical and animal experiments have shown that Vonoprazan is more resistant to PPI or H2 receptors than PPI or H2 receptors. The onset of lag agent is faster, the effect of increasing pH is stronger, it can quickly relieve the symptoms of digestive tract, the enzyme activity recovers after dissociation, and there are few adverse reactions. The prevention and treatment of gastric and duodenal ulcers, and the eradication of Helicobacter pylori as a first-line treatment plan have significant therapeutic effects. The curative effect is higher than that of lansoprazole, and the adverse reactions are small.
2. Vonorazan has high lipophilicity and high dissociation constant. It can take effect without acid activation in an acidic environment. The inhibitory effect of vonoprazan on the proton pump does not require acid activation, enters the stomach at high concentrations, and produces the greatest inhibitory effect after the first dose, and lasts for 24 hours. Vonolazan is stable in acid, can rapidly increase the pH value in the stomach, and exert an acid-suppressing effect.
3. At the therapeutic dose, vonoprazan has little effect on other enzymes, little effect on the physiological function of the body, good safety and easier tolerability.